Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
Spero Therapeutics, Inc. (SPRO)
Last spero therapeutics, inc. earnings: 3/16 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.sperotherapeutics.com/overview
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced financial results for the first quarter ended March 31, 2019 and provided a pipeline review. “We have made significant progress to date in 2019 advancing our pipeline candidates, including the initiation of our pivotal Phase 3 trial of oral SPR994 for the treatment of cUTI,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “We look forward to providing updates on the SPR994 Phase 3 trial, as well as reporting out Phase 1 data from our SPR720 and SPR206 clinical trials in the second half of 2019.” Recent Clinical Highlights and Upcoming Milestones SPR994: Spero’s lead product candidate, SPR994, has the potential to be th
Show less
Read more
Impact Snapshot
Event Time:
SPRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRO alerts
High impacting Spero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SPRO
News
- Spero Therapeutics Delivers On Game Plan To Create Shareholder Value [Seeking Alpha]Seeking Alpha
- Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Spero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
- Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
SPRO
Earnings
- 3/13/24 - Beat
SPRO
Sec Filings
- 4/16/24 - Form ARS
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- SPRO's page on the SEC website